Description:
This therapeutic strategy is directed to the use of small interfering RNAs that target host factors, namely anthrax toxin receptors ANTXR1 and ANTXR2. The reduction of expression of ANTXR1 and ANTXR2 leads to the inhibition of endocytosis of anthrax toxins, which is a significant part of the toxicity mechanism. Furthermore, this strategy uses RNA interference to target proinflammatory cytokine expression in macrophages to prevent anthrax-toxin-induced shock. When used in combination with current antibiotics, this technology would improve anthrax treatment in patients who have already begun experiencing anthrax symptoms.
Reference Number: D-0885
Market Applications:
• Pharmaceuticals
• Health Care
• Bio-Terrorism
Features, Benefits & Advantages:
Currently, the only drugs used to treat anthrax are effective only prior to the onset of symptoms. This technology, when used in combination with current antibiotic treatment, would significantly improve the treatment of anthrax for patients who have already begun experiencing symptoms.
• Great Potential for new drug
• Earlier detection of falls alongside tracking of other life activities
Intellectual Property:
A PCT patent application was filed for the technology on 06/12/2014
Development Stage:
The technology has been produced and tested. Preliminary experimental data have provided proof of concept..
Researchers:
Mingtao Zeng, Biomedical Sciences, Texas Tech University Health Sciences Center, El Paso, Texas.
Maria Arevalo, Postdoctoral Research Associate, Texas Tech University Health Sciences Center, El Paso, Texas.
Publications:
Targeted Silencing of Anthrax Toxin Receptors Protects against Anthrax Toxins. May 30, 2014 The Journal of Biological Chemistry, 289, 15730-15738. doi: 10.1074/jbc.M113.538587
Keywords:
antrhrax, ANTXR1, ANTSR2, RNA interference, endocytosis, proinflammatory cyctokine expression, antibiotics